**To the Editor:** Following logic similar to that recently used by the US Food and Drug Administration to withdraw approval for enrofloxacin, a recent letter estimated that fluoroquinolone use in poultry could compromise responses to antimicrobial drugs in \>24,000 persons per year in the United States ([@R-1-1]). However, \>99.9% of this estimated risk appears to result from incorrect assumptions. Potentially important corrections include the following: 1) not attributing resistance from foreign travel and human ciprofloxacin use to domestic use of enrofloxacin in poultry (this could reduce the estimated risk by ≈1/3) ([@R-1-2]); 2) updating the estimated fraction of human foodborne *Campylobacter* infections caused by poultry to reflect declines in microbial loads on chicken carcasses since 1992 reduces the estimated risk by a factor of perhaps 1/10 ([@R-1-3]) (the cited 90% estimate by Hurd et al. \[[@R-1-1]\] was intended for use as part of a conservative upper-bounding analysis, not as a realistic point estimate); 3) replacing an assumption that 10% of infected persons would benefit from antimicrobial drug therapy with a more data-based value of 0.6% ([@R-1-4]) would reduce the estimated risk by a factor of 0.6/10 = 0.06; 4) replacing an assumption that fluoroquinolones are prescribed for *all* affected patients receiving antimicrobial drug treatment (rather than, for example, erythromycin) by a more realistic value of fluoroquinolones being prescribed for perhaps ≈50% of patients ([@R-1-2]) reduces the estimated risk by a factor of ≈50%; 5) replacing an assumption that *all* such cases lead to compromised responses with a more data-driven estimate that perhaps ≈17% of patients have compromised responses would reduce the estimated risk by a factor of 1/6 ([@R-1-5]); and 6) recognizing that reducing enrofloxacin use may not decrease fluoroquinolone resistance in all *Campylobacter* spp. from food animals (effect not quantified) ([@R-1-6]). Together, such changes reduce the estimated risk by a factor of at least (1/3) × (1/10) × (0.6/10) × (1/2) × (1/6) = 0.00017, or by \>99.9%.

More notably, the calculation in ([@R-1-1]) also wrongly assumes that the fraction of patients with fluoroquinolone-resistant infections times the fraction of infections caused by poultry gives the fraction of patients with compromised response caused by fluoroquinolone use in poultry. As a simple counterexample, suppose that 80% of all infections were caused by poultry, with the rest caused by something else (e.g., water), and that all and only the 20% of infections caused by the latter source are resistant. Then the procedure in ([@R-1-1]) would estimate (80% of infections caused by poultry) × (20% of infections resistant) = 16% as the fraction of resistant infections caused by poultry, even though the correct answer is zero. Thus, the basic logic of the calculation is flawed.
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**In response:** Cox\'s letter ([@R-2-1]) contains a number of false assumptions, errors, misleading assertions, and misquotations. Cox asserts that annually 1 person or fewer in the United States will experience an adverse effect because of fluoroquinolone use in poultry. He reduces 10-fold my referenced risk for persons acquiring *Campylobacter* infections from poultry ([@R-2-2]). His unrealistically low estimate is not given in his referenced citation. His estimated risk is also much lower than in the reference [@R-2-2], which Cox himself quotes, \"Poultry is the most common cause of sporadic cases of campylobacteriosis in the United States\" (Economic Research Service of the US Department of Agriculture) ([@R-2-3]). Cox knows that his assertion ([@R-2-4]) that poultry make little or no contribution to human *Campylobacter* infections has been extensively examined and found to be wrong. Indeed, an entire section in a recent US Food and Drug Administration (FDA) determination was written about the unreliability of Cox\'s testimony and these assertions, a finding made by both the FDA commissioner and an administrative law judge ([@R-2-5]*,*[@R-2-6]).

Cox also misquotes Busby et al. ([@R-2-3]) when he asserts that only 0.6% of persons with *Campylobacter* infections benefit from antimicrobial drugs. The Busby article states that 0.6% of persons with *Campylobacter* infections need \"hospitalization,\" not how many would benefit from antimicrobial drug therapy. Cox has thus made a misleading attribution (something he has previously been found to do \[[@R-2-5]\]).

Busby et al. ([@R-2-3]) estimated that in 1993, ≈1,500,000 persons in the United States acquired *Campylobacter* infections from food sources. Even if the proportion who can benefit from receiving antimicrobial drugs is as low as 2%, this translates to 30,000 persons. If 20% of these infections were caused by fluoroquinolone-resistant *Campylobacter* spp., then 6,000 persons would potentially have their therapy and outcome compromised, rather than the 1 person that Cox would have us believe. More realistic is the figure of 24,000 persons estimated previously to be at risk of having an adverse outcome (or ≈285 persons for every 1 million chickens treated with fluoroquinolones) ([@R-2-1]). Cox\'s assumptions and calculations thus seem flawed and unrealistic.
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